Panagora Asset Management’s Calithera Biosciences, Inc CALA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-128
Closed -$5K 2747
2021
Q2
$5K Sell
128
-23,149
-99% -$1.02M ﹤0.01% 2508
2021
Q1
$1.13M Buy
23,277
+2,675
+13% +$156K 0.01% 971
2020
Q4
$2.02M Buy
20,602
+6,252
+44% +$548K 0.01% 710
2020
Q3
$990K Buy
14,350
+7,600
+113% +$663K 0.01% 901
2020
Q2
$713K Buy
6,750
+5,301
+366% +$630K ﹤0.01% 1062
2020
Q1
$129K Buy
1,449
+674
+87% +$80.3K ﹤0.01% 1601
2019
Q4
$89K Hold
775
﹤0.01% 1825
2019
Q3
$48K Buy
775
+7
+0.9% +$560 ﹤0.01% 1975
2019
Q2
$60K Buy
+768
New +$87.2K ﹤0.01% 2060
2018
Q3
Sell
-53
Closed -$5K 2489
2018
Q2
$5K Sell
53
-2,476
-98% -$281K ﹤0.01% 2311
2018
Q1
$319K Sell
2,529
-3,551
-58% -$554K ﹤0.01% 1533
2017
Q4
$1.01M Sell
6,080
-3,136
-34% -$803K ﹤0.01% 1128
2017
Q3
$2.9M Buy
9,216
+3,787
+70% +$1.19M 0.01% 725
2017
Q2
$1.61M Buy
+5,429
New +$1.45M 0.01% 942
2016
Q2
Sell
-2,165
Closed -$246K 2366
2016
Q1
$246K Buy
2,165
+85
+4% +$9.63K ﹤0.01% 1591
2015
Q4
$319K Buy
+2,080
New +$312K ﹤0.01% 1459

Other funds holding CALA

Panagora Asset Management's CALA Position: Q3 2021 in Review

Panagora Asset Management sold out of Calithera Biosciences, Inc (CALA) in Q3 2021, closing a stake of 128 shares — an estimated $5K sold.

Panagora Asset Management first reported a position in CALA in Q4 2015 and held it in 16 quarters. The position peaked at $2.9M in Q3 2017. 66 funds tracked by Wall St. Rank hold CALA as of Q3 2021.

  • Panagora Asset Management reported no remaining Calithera Biosciences, Inc position as of Q3 2021 after selling out during the quarter.
  • Panagora Asset Management sold 128 Calithera Biosciences, Inc shares in Q3 2021, an estimated $5K.
  • Panagora Asset Management first reported a position in Calithera Biosciences, Inc in Q4 2015 and held it in 16 quarters.
  • Panagora Asset Management's Calithera Biosciences, Inc position peaked at $2.9M in Q3 2017.
  • 66 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q3 2021.

Based on Panagora Asset Management's 13F filing for Q3 2021, filed 10 Nov 2021.